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HER2 overexpression and anti-HER2 agents represent probably the best story of success
of individualized therapy in breast cancer. Due to the important therapeutic implications,
the issue under the spotlight has been, since ever, the correct identification of true HER2
positivity on tissue specimens. Eligibility to anti-HER2 agents is strictly dependent on
the demonstration of HER2 overexpression (by immunohistochemistry) or of HER2 gene
amplification by in situ techniques (fluorescence in situ hybridization, FISH), however there
are controversial issues involving cases with “equivocal” HER2 status based on conven-
tional techniques (about 20% of specimens). In terms of HER2 expression a major debate
is the presence of full-length and truncated forms of the protein and controversial clin-
ical data have been reported on the therapeutic implications of these HER2 fragments.
In terms of HER2 gene assessment, the occurrence of amplification of the chromosome
17 centromeric region (CEP17) has been proven responsible for misleading HER2 FISH
results, precluding anti-HER2 based therapy to some patients. Finally HER2 activating
mutations have been recently described as a biological mechanisms alternative to HER2
gene amplification. In this review we will focus on the controversies that pathologists and
oncologists routinely face in the attempt to design the most tailored treatment for breast
cancer patients. We will focus on the HER2 gene and on the protein, both at technical and
interpretational levels.
Keywords: HER2, truncated HER2, CEP17 amplification, HER2 mutations, diagnosis, therapy, test
INTRODUCTION
HER2, a member of the human epidermal growth factor receptor
family, is an orphan tyrosine kinase receptor that is overexpressed
in 15–20% of breast cancers and these carcinomas show a poor
prognosis (Slamon et al., 1987; Marchiò and Reis-Filho, 2008).
HER2 overexpression is a direct result of gene amplification in
∼95% of cases and represents perhaps the best target for individ-
ualized therapy because it has been shown to be a tumor driver
and an excellent example of “oncogene addiction” (Slamon et al.,
1987; Marchiò and Reis-Filho, 2008). The humanized mouse mon-
oclonal antibody Herceptin® (namely trastuzumab) targeting the
extracellular domain (ECD) of HER2 is nowadays offered to breast
cancer patients in advanced, adjuvant, and neoadjuvant settings in
association with chemotherapy. Moreover, in the case of metastatic
HER2+ breast cancer a tyrosine kinase inhibitor, lapatinib (Geyer
et al., 2006), as well an antibody targeting HER2-HER3 dimeriza-
tion, pertuzumab (Baselga et al., 2012), have also been approved
by U.S. Food and Drug Administration (FDA) for treatment in
combination with chemotherapy.
The introduction of such a tailored therapeutic option has had
a tremendous impact on the natural history of HER2-positive
disease over the years and, due to the important therapeutic impli-
cations, the issue under the spotlight has been, since ever, the
correct identification of true HER2 positivity on tissue specimens.
The relevance of such assessment on HER2+ breast cancer care
will be further enhanced if trastuzumab is administered to patients
in monotherapy. Indeed, studies to improve drug effectiveness of
trastuzumab led to the development of trastuzumab emtansine
(i.e., trastuzumab-DM1, T-DM1), an antibody-drug conjugate
consisting of trastuzumab linked to the cytotoxin mertansine
(DM1). T-DM1 is designed to target and inhibit HER2 sig-
naling and to deliver the chemotherapy directly inside HER2+
cancer cells. At present T-DM1 is currently being employed in
clinical trials (Bose et al., 2013; Peddi and Hurvitz, 2013): a
phase II randomized trial of T-DM1 in the front-line metastatic
breast cancer setting has revealed promising activity and improved
safety compared with standard chemotherapy plus trastuzumab
(Hurvitz et al., 2012); in addition a phase III trial in patients
with trastuzumab-pretreated metastatic breast cancer showed T-
DM1 to be associated with prolonged progression-free and overall
survival compared with lapatinib plus capecitabine (Verma et al.,
2012).
T-DM1 represents a paradigm shift in the treatment of breast
cancer patients and in such a scenario it is mandatory to pre-
cisely recognize HER2+ carcinomas, because patients will not be
administered any other chemotherapeutic agents and response to
treatment will strictly rely on pathological assessment of HER2.
HER2 STUDY IN DIAGNOSTIC PRACTICE TODAY:
A PRAGMATIC OVERVIEW
Based on the premises above, it is not surprising that in a standard
day of routine diagnostic practice HER2 scoring, along with the
assessment of other prognostic and predictive factors, is undoubt-
edly one of the topic moments in terms of breast cancer pathology.
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Before getting down into the nitty gritty details of the methodol-
ogy there are some questions that need to be answered regarding
where and when we should test HER2. As detailed above, anti-
HER2 agents are currently being offered as a standard of care both
in early-stage and metastatic breast cancer. In terms of neoadju-
vant setting one caveat should be spelled out in terms of adequacy
of specimens. Neoadjuvant therapy is planned for patients with
locally advanced carcinomas or with tumors primarily not suitable
for breast-conserving surgery, thus the first aim of this therapeutic
option is to downsize the disease burden and possibly to achieve
pathologic complete response (pCR) (Marchio and Sapino, 2011).
In order to target the disease it is mandatory to have a proper
sampling of the lesion to account for tissue heterogeneity at histo-
logical and immunophenotypical level, which represents a crucial
factor for treatment decision making and finally for the success of
the therapy. Although international guidelines are not available on
the topic, in our routine experience sampling of different tumor
areas by core biopsy (three biopsies on average) is helpful to define
the precise nature of the lesion, the different tumor histological
types present in the mass, and the heterogeneity in the expres-
sion of predictive markers (Marchio and Sapino, 2011). Following
neoadjuvant treatment surgery is performed and proper histolog-
ical documentation of residual disease is mandatory in association
with re-testing of prognostic and predictive factors (Marchio and
Sapino, 2011).
Other hot topic about timing of HER2 testing is represented by
metastatic disease. Several studies have demonstrated a discrep-
ancy between primary and metastatic tumors (Gancberg et al.,
2002; Regitnig et al., 2004; Gong et al., 2005; Fabi et al., 2011). Based
on the fact that change in the phenotype may mean the possibility
to add a precious and potentially life-saving therapeutic option,
HER2 reassessment in metastatic lesions should be carefully taken
into account, whenever feasible, especially for metastases coming
from primary hormone receptor-positive breast cancer (Fabi et al.,
2011).
BEST LABORATORY PRACTICE
The methodological approach depends on the laboratory organi-
zation, as two FDA-approved techniques are available. Although
they can be used indiscriminately, usually the first step is rep-
resented by the assessment of HER2 protein overexpression in
immunohistochemistry (IHC), which contemplates a well known
four-tier scoring system. Scores 0 and 1+ are considered as nega-
tive (no eligibility to anti-HER2 treatment), score 3+ is considered
as positive (eligibility to anti-HER2 treatment), whereas score 2+
[up to 24% of all cases (Lee et al., 2011)] constitutes a gray zone
in which further tests are needed (Wolff et al., 2007). However, the
IHC scoring system is not so robust and the cut-off value (percent-
age of cells to be positive) across different score classes has been
changing over time. Recently Perez et al. (2012) call for the atten-
tion on the differences between the FDA scoring system for HER2
expression (10% cut off) used in some adjuvant trastuzumab tri-
als and the one proposed by the ASCO/CAP guidelines (30% cut
off), showing that the latter determined a certain rate of false neg-
ative HER2 tumors. On the other hand, the answer of some of
the ASCO/CAP guideline authors (Wolff et al., 2012) was that this
scoring system reduces the number of false-positive results. In any
case the moderate expression of HER2 (2+) even without HER2
gene amplification is a negative prognostic factor in early breast
cancer (Rossi et al., 2012).
Regarding HER2 gene status, three FDA approved in situ
hybridization techniques are available: fluorescence in situ
hybridization (FISH), chromogenic in situ hybridization (CISH),
silver in situ hybridization (SISH). Very recently a “fast FISH” has
been developed (IQFISH) (Matthiesen and Hansen, 2012): this
technology exploits alternative solvents and a new hybridization
buffer that reduces the required hybridization time to 1 h, thus
shortening the turnaround time from sample to diagnosis without
affecting output results (a concordance of 98% with conventional
FISH has been proven) (Matthiesen and Hansen, 2012).
For in situ hybridization analysis two scoring systems with dis-
tinct thresholds for HER2 gene copy number and HER2/CEP17
ratio are available. Indeed, the FDA and ASCO/CAP schemes for
HER2 evaluation differently select patients for trastuzumab ther-
apy. Amplification is defined as: (i) HER2/CEP17 >2 or HER2
copy number>4 according to FDA (Jacobs et al., 1999; Birner et al.,
2001; Brunelli et al., 2008); (ii) HER2/CEP17 >2.2 or HER2 copy
number>6 according to ASCO/CAP. The latter scoring system has
introduced the “equivocal” range, in which fall those cases harbor-
ing a HER2 copy number between 4 and 6 or a HER2/CEP17
between 1.8 and 2.2. Of note, the minimal thresholds of >4 gene
copy number is required as replicating cells (G2 phase, in anticipa-
tion of cell division) will have four copies of chromosome 17 and
HER2 gene, therefore breast tumors with normal HER2 status but
high proliferative activity may have a mean HER2 copy number
up to 4 (Ross et al., 2003; Szollosi et al., 2005).
From a technical standpoint, in order to guarantee the best IHC
and FISH performance, technicians as well as molecular biologists,
and pathologists are demanded to work in close collaboration and
key points in pre-analytical, analytical, and post-analytical phases
of HER2 testing have been identified, as largely detailed in the
ASCO/CAP guidelines (Wolff et al., 2007). Issues about repro-
ducibility and reliability of HER2 testing have always been a matter
of debate among pathologists (Wolff et al., 2007) and some of the
major problems affecting such reproducibility are discussed here
below.
As an example, for the pre-analytical phase bold claims have
been recently made about the impact cold ischemia time (i.e.,
time to fixation) may have on HER2 testing (Pekmezci et al., 2012;
Yildiz-Aktas et al., 2012a,b). The shorter the cold ischemia time the
better is the quality of HER2 staining (Pekmezci et al., 2012; Yildiz-
Aktas et al., 2012a,b), and results are poorer for non-refrigerated
samples (Yildiz-Aktas et al., 2012a). Ideally cold ischemic time
should not exceed 1 h, then, upon sampling formalin fixation (10%
neutral buffered formalin) should be applied within a time frame
comprised between 6 and 48 h (Wolff et al., 2007). However, con-
trolling the time of fixation is a difficult matter, because immersion
in formalin of a large surgical specimen does not mean initiation of
fixation of a tumor. Our group has successfully explored the under
vacuum sealing of large specimens and cooling at 4˚C for trans-
port from the surgical theater to the pathology lab as a method
that allows monitoring exactly the time of ischemia and of initia-
tion of fixation and guarantees an optimal preservation of antigens
(Bussolati et al., 2011; Comanescu et al., 2012).
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In terms of analytical phase the availability of distinct antibod-
ies and their specificity can take part in affecting reproducibility
of results. FDA-approved anti-HER2 antibodies for IHC (Wolff
et al., 2007) are directed against the intracellular domain. In
routine diagnosis it is suggested to use kit preparations such
as: pathway HER2 (clone 4B5; Ventana Medical Systems Inc.,
Tucson, AZ, USA), HercepTest (Dako, Glostrup, Denmark), and
Oracle HER2 (clone CB11; Leica Microsystems GmbH, Wetzlar,
Germany). In a recent work it has been shown that all three anti-
bodies react with HER2 proteins and peptides in IHC stainings,
ELISA, and immunoblotting. However, while HercepTest shows
no cross-reactivity with other proteins of the HER family, the
others cross-react with HER4 (Schrohl et al., 2011). Antibodies
targeting the ECD are commercially available (such as Tab250,
Invitrogen, San Diego, CA, USA), however none of them recog-
nizes the trastuzumab binding site (epitope in the cysteine rich
region of the IV domain, in proximity of the juxtamembrane
region). The only antibody targeting the trastuzumab binding site
is the 4D5 (Genentech, Inc., San Francisco, CA, USA), the murine
monoclonal, later humanized as trastuzumab (Herceptin®), which
is not commercially available. In our lab we developed a biotiny-
lated form of Herceptin®, the BiotHER (Bussolati et al., 2005;
Sapino et al., 2007), which can be used in formalin fixed paraf-
fin embedded (FFPE) tissues. BiotHER positivity, in a large series
of advanced breast cancers treated with Herceptin®, showed a sig-
nificant correlation with response (Bussolati et al., 2005; Sapino
et al., 2007).
FOCUS ON POST-ANALYTICAL PHASE: INTRA-TUMORAL
HETEROGENEITY
Interpretation and reporting are crucial moments, especially when
dealing with in situ hybridization. A real challenge and widely dis-
cussed matter of debate is represented by intra-tumoral HER2
heterogeneity. If on one side decisions for therapy require a yes/no
answer, in the other HER2 status derives from a continuum of
gene copy number and protein expression (Oakman et al., 2010),
especially in equivocal cases. As said above, the widely adopted
ASCO/CAP guidelines (Wolff et al., 2007) have implemented
stricter thresholds (30% versus 10%) to improve detection reli-
ability, accuracy, and reproducibility of IHC and FISH with the
final aim to ameliorate the concordance between IHC and FISH
analyses, leading to a narrower selection of population eligible
for trastuzumab treatment (Wolff et al., 2007). In addition, they
do not take a position about intra-tumoral heterogeneity, as they
read “If genomic heterogeneity of HER2 gene amplification is found,
it must be specifically reported (Hicks and Tubbs, 2005; Wolff et al.,
2007). No consensus recommendations exist at this time for handling
of genomic heterogeneity” (Wolff et al., 2007). HER2 genetic het-
erogeneity is defined as the presence of more than 5% but less than
50% of infiltrating tumor cells with a HER2/CEP17 ratio higher
than 2.2 (Vance et al., 2009).
According to this definition (Vance et al., 2009), HER2 het-
erogeneity ranges between 5% (Vance et al., 2009) and 15%
(Ohlschlegel et al., 2011) of total cases tested and seems to be most
frequent (up to 27%) in breast carcinomas with an equivocal (2+)
HER2 score (Ohlschlegel et al., 2011). In a recent study, genetic
heterogeneity was associated with a negative HER2 amplification
status in 16% of all carcinomas and 42% of HER2 (2+) carci-
nomas, respectively (Ohlschlegel et al., 2011). This means that
the group of HER2 amplification-negative carcinomas comprise
a subgroup of HER2 genetic heterogeneity-positive carcinomas
that harbor a significant subpopulation (>5%) of tumor cells with
HER2 amplification but do not qualify for trastuzumab treatment
based on current recommendations (HER2/CEP17 ratio – calcu-
lated on the overall population – below 2.2) (Ohlschlegel et al.,
2011).
About heterogeneity a distinction should be made, as in gen-
eral two main types of such a phenomenon can be encountered
and may have distinct implications. The first one is represented
by presence of two distinct populations of cells (i.e., two different
clones of cancer cells within a lesion), one completely negative for
HER2 and the other clearly positive (HER2 amplified) (Oakman
et al., 2010). Such a scenario may be assimilated to the so-called
“focal HER2 amplified clones”(FHACs), which have been reported
in an N9831 substudy (Miller et al., 2004). FHACs were defined
as having 2–40% of cells with unequivocal amplification (cells
with >10 HER2 signals or HER2/CEP17 ratio >5, regardless of
overall HER2/CEP17 ratio) (Miller et al., 2004) and were detected
particularly in tumors with discordance between HER2 status by
IHC and FISH (21% of IHC 0–1/FISH-amplified and 30% of
IHC2+/FISH-amplified cases contained FHACs) (Miller et al.,
2004). The therapeutic implications of this finding have been
explored in 91 patients from N9831 with FHAC and compared
with 1571 patients with diffuse HER2 amplification (Sukov et al.,
2009) and a similar trastuzumab benefit was seen for patients with
HER2 amplification, either diffuse or focal (Oakman et al., 2010).
The second type of heterogeneity, which leads to consider-
able troubles in FISH reporting, is represented by those tumors
in which scattered HER2 amplified cells are identified within a
homogeneous background of cells that substantially lack HER2
gain or amplification (Oakman et al., 2010). The biological mean-
ing of such a scenario is much more controversial and probably
recommendations would benefit from definition of a cut-off for
the cell population harboring HER2 amplification.
“NEWS AND VIEWS” FROM EXPERIMENTAL STUDIES ON
HER2
In this paragraph we will focus on recent experimental studies
that have brought to the forefront phenomena that can affect
HER2 identification, interpretation/reporting, and response to
treatment. In terms of HER2 expression a major debate is rep-
resented by the presence of full-length or truncated/fragmented
forms of the protein. In terms of HER2 gene assessment, the recent
demonstration of occurrence of amplification of the centromeric
region of chromosome 17 (CEP17) can be responsible for mis-
leading HER2 FISH results, precluding a potentially life-saving
treatment to breast cancer patients.
TRUNCATED HER2 PROTEIN
Although the HER2 gene encodes for the full-length membrane-
spanning receptor p185HER2, approximately 30% of HER2+
tumors express a variety of receptor fragments sized between
90 and 115 kDa, collectively known as p95HER2 carboxy-terminal
fragments (CTFs) (Parra-Palau et al., 2010; Recupero et al., 2013).
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p95HER2 is described to be consistently found in a subset of HER2-
positive carcinomas (Arribas et al., 2011; Zagozdzon et al., 2011),
i.e., in the presence of high levels of p185HER2 (Recupero et al.,
2013) and therefore in HER2 amplified cases (Recupero et al.,
2013).
Two main mechanisms can lead to the formation of p95HER2
fragments: the proteolytic cleavage mediated by alpha-proteases
(Codony-Servat et al., 1999) and translation of the mRNA encod-
ing HER2 from internal initiation codons (Christianson et al.,
1998; Anido et al., 2006; Arribas et al., 2011). Proteolytic cleavage
results in the formation of two receptor fragments, i.e., the soluble
p105 fragment of ECD (released in the extracellular compartment)
and the oncogenic 95- to 100-kDa p95HER2 fragment (648-CTF),
which is anchored to the plasma membrane. A disintegrin and
metalloproteinase 10 (ADAM10) has been identified as a major
source of shedding of the ECD of HER2 in HER2+ breast cancer
cells (Liu et al., 2006). By alternative initiation of translation two
p95HER2 fragments are generated, of 100- to 115-kDa (611-CTF)
and 90- to 95-kDa (678-CTF), respectively. Pedersen et al. (2009)
have analyzed the activity of the individual p95HER2 fragments
and showed that the soluble intracellular 90-to 95-kDa fragment
(678-CTF) was inactive, despite having an intact kinase domain
(Pedersen et al., 2009), whereas the membrane-bound p95HER2
fragments were active. Although the activity of the 95- to 100-kDa
fragment (648-CTF) was comparable with that of the full-length
receptor, expression of the 100- to 115-kDa fragment (611-CTF)
led to a much more rapid and acute activation of different sig-
naling cascades (Pedersen et al., 2009). As a result, expression of
the 100- to 115-kDa p95HER2 fragment (611-CTF) leads to the
regulation of a specific set of genes not regulated by full-length
HER2 (Pedersen et al., 2009) that are involved in the metasta-
tic progression (Pedersen et al., 2009). In addition, this fragment
has been recently shown to play a role in the intertalk with the
estrogen receptor (ER) during malignant progression: it has been
demonstrated that 611-CTF induces resistance to anti-estrogen
therapy and a more pronounced down-modulation of ER than that
induced by full-length HER2 (Parra-Palau et al., 2010; Recupero
et al., 2013).
Overall, p95HER2 is clinically associated with aggressive dis-
ease, poor prognosis, and, by lacking the trastuzumab binding
epitope, it has been implicated also as a mechanism of resistance
to the antibody (Molina et al., 2001, 2002; Saez et al., 2006; Scaltriti
et al., 2007; Guarneri et al., 2012). The latter observation has been
recently called into question by the results from the neoadjuvant
GeparQuattro study (chemotherapy plus trastuzumab treatment),
which has showed that p95HER2 expression, measured by using a
monoclonal antibody that specifically recognizes the 611-CTF in
IHC, indicates response to the neoadjuvant trastuzumab-based
regimen (Loibl et al., 2011). The results from the GeparQuat-
tro study open a new, yet controversial, perspective in terms of
trastuzumab-based therapy, that may be explained, at least in
part, by recently reported experimental data (Recupero et al.,
2013). Indeed, we have analyzed a series of breast carcinoma
for p95HER2 by using western blot and compared the results
with IHC for both intracellular domain (CB11) and trastuzumab
binding site [by using BiotHER (Bussolati et al., 2005; Sapino
et al., 2007)]. Surprisingly we observed a significantly higher
percentage of 3+ scored cells (with both antibodies) in p95HER2-
positive cases, suggesting that p95HER2 does not compromise the
immunohistochemical detection of HER2 and does not affect the
trastuzumab binding site (Recupero et al., 2013). A possible expla-
nation for this unexpected increase in immunoreactivity of the
anti-HER2 antibodies in the presence of p95HER2 may be the
reduction of the antigen“steric hindrance”(Kent et al., 1978; Recu-
pero et al., 2013): if the antigen molecules are closely “packed”
on the cell surface, spatial interference may result leading to a
greater likelihood of reduced antibody binding. This hypothe-
sis was proven by experimental studies in an in vitro model of
p95HER2 expressing breast cancer cells obtained via culturing the
HER2+ BT474 cells with pronase, a cocktail of 10 proteases.
Indeed, short-term pronase digestion of BT474 cells (i) produced
two HER2 fragments (of 95 and 150 kDa), (ii) increased the
binding affinity of trastuzumab, (iii) reduced the rate of HER2-
HER3 dimers, (iv) and did not interfere with pertuzumab-binding
capacity (Recupero et al., 2013). We may therefore conclude that
p95HER2 is likely to foster a reduction of the antigen “steric hin-
drance,” thus facilitating the binding capacity of trastuzumab
(Figure 1).
FACTS AND ARTIFACTS ABOUT CHROMOSOME 17 POLYSOMY
Assessment of HER2 gene status by dual-color FISH can be trou-
blesome sometimes (Isola et al., 2004; Troxell et al., 2006; Wolff
et al., 2007; Marchio et al., 2009), in particular for tumors dis-
playing abnormal copy numbers of CEP17 (Marchio et al., 2009).
Polysomy of chromosome 17 defined by dual-color FISH as a
mean of CEP17 copy number higher than three is observed in
approximately 8% of all breast cancer specimens (Ma et al., 2005;
Reddy et al., 2006; Wolff et al., 2007; Marchio et al., 2009), mostly
among cases with four to six HER2 gene copies (the so-called
“equivocal range” of FISH assessment) (Ma et al., 2005; Reddy
et al., 2006; Marchio et al., 2009). However, we should keep in
mind that polysomy is a cytogenetic definition and represents the
occurrence in a nucleus of extra copies of one or more individual
chromosomes (Marchio et al., 2009), therefore, per se, it can only
be inferred from dual-color FISH on interphase nuclei (Figure 2).
By coupling FISH and microarray-based comparative genomic
hybridization (aCGH) analysis we have provided the first direct
evidence that additional copies of CEP17 as detected by FISH
are frequently caused by CEP17 gain/amplification (Figure 2)
and that these phenomena are more prevalent than true chromo-
some 17 polysomy (38.9/55.5 versus 5.5%, respectively) (Marchio
et al., 2009). This demonstration, subsequently validated by inde-
pendent groups employing other techniques (Yeh et al., 2009;
Moelans et al., 2010, 2011b; Varga et al., 2012), holds important
clinico-therapeutic implications, as the occurrence of amplifica-
tion of CEP17 can be responsible for misleading HER2 FISH
results due to the HER2/CEP17 ratio (Figure 2), precluding there-
fore anti-HER2 based therapy to some patients (Marchio et al.,
2009).
One may ask whether, as pathologists, we are still doing a good
job by following the ASCO/CAP recommendations and in partic-
ular the analysis of results based on the HER2/CEP17 ratio. Some
(Troxell et al., 2006; Tse et al., 2011) have recommended the use
of probes for additional chromosome 17 loci (SMS and RARA
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FIGURE 1 | Steric hindrance phenomenon. Immunohistochemistry
for the trastuzumab binding site (BiotHER staining) shows higher
intensity in cell block sections of BT474 cells treated with 0.1%
pronase and in pronase-treated (as “antigen retrieval”) cell block
sections of BT474 cells. This is likely to be due to a matter of steric
hindrance, according to which if antigen molecules are closely
“packed” on the cell surface, spatial interference results in a greater
likelihood of reduced antibody binding.
mapping to 17p11.2 and 17q21.2, respectively) as surrogate chro-
mosome 17 controls in cases with a complex CEP17 FISH pattern,
whilst others have claimed the use of aCGH in routine diagnostic
practice (Yeh et al., 2009; Gunn et al., 2010). Although these tech-
niques may provide additional information they do not provide
a definitive answer in all of the cases (Marchio et al., 2009). We
believe that results based upon HER2/CEP17 ratio are still a good
indicator of HER2 amplification, provided that in those cases har-
boring aberrant CEP17 copy numbers calculation is performed
based on absolute HER2 copy numbers (HER2>6) (Viale, 2009).
In terms of misleading HER2/CEP17 ratio values a final remark
should be made about another potential pitfall. It has been shown
that HER2 gene-amplified breast cancers with monosomy of chro-
mosome 17 are poorly responsive to trastuzumab-based treatment
(Risio et al., 2005). Indeed, a word of caution should be spelled
out for those cases showing either chromosome 17 monosomy
or loss of the short arm of chromosome 17 involving the cen-
tromeric region. In such a scenario the mean CEP17 copy number
as calculated by FISH is consistently lower than 2, therefore a “dili-
gent” application of the ratio, in presence of normal/low increase
of HER2 copy numbers, would lead to values higher than 2 or
2.2 without an underlying HER2 amplification. As a consequence,
in such cases HER2 copy number should be taken into account
instead of the ratio.
HER2 STUDY IN DIAGNOSTIC PRACTICE IN THE FUTURE:
POSSIBLE SCENARIOS?
At present the long awaited update of ASCO/CAP guidelines are
soon to be published, and we expect to face amendments in terms
of scoring methods and cut-offs that may affect both pathology
practice and oncology treatment decision making.
Beyond adjustments to scoring methods, breast diagnostic
pathology may have to deal in the near future with two main issues,
of which one is purely methodological and the other biological.
The methodological issue contemplates the possible introduc-
tion of new/alternative techniques to be incorporated in HER2
testing. Given the gray area of HER2 assessment as well as the
recent description of CEP17 amplification that has generated skep-
ticism about the HER2/CEP17 ratio, some have hypothesized that
implementation of other assays would help sort out difficult cases.
Over the past 5 years or so, multiplex ligation-dependent probe
amplification (MLPA) has emerged as a robust technique for HER2
testing. MLPA is a PCR-based technique that requires minute
quantities of DNA isolated from FFPE material (50–200 ng) and
uses multiple probes (up to 45) directed against target and con-
trol genes in each PCR run (Farshid et al., 2011; Moelans et al.,
2011a). This technique was introduced in 2002 and over the
years has gained widespread clinical acceptance for the identifi-
cation of gene copy number changes in a broad range of genetic
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FIGURE 2 | Chromosome 17 polysomy versus CEP17
gain/amplification. Possible scenarios in which additional CEP17 signals
are encountered, from top to bottom: true chromosome 17 (chr17)
polysomy without HER2 gene amplification; gain/amplification of CEP17
without HER2 amplification; HER2 amplification in a context of chr17
polysomy; HER2 amplification coupled with CEP17 gain/amplification. In
all scenarios the ratio is below 2.2, however in the latter two cases HER2
amplification is present (HER2 mean copy number >6).
diseases to identify aneuploidy and trisomies, and more recently
for HER2 amplification (White et al., 2004; Jankowski et al., 2008;
Kozlowski et al., 2008; Farshid et al., 2011). A probe set for the
measurement of HER2 gene amplification is commercially avail-
able (P004-C1 ERBB2 probemix MRC Holland). This probe set
includes 49 MLPA probes of which 4 map to HER2 (different seg-
ments of the gene), and 12 map to reference genes. MLPA has been
compared with FISH/CISH and IHC with a concordance of 97%
(Moerland et al., 2006) and 89% (Purnomosari et al., 2006) respec-
tively, thus suggesting MLPA is a reliable technique to measure
HER2 amplification in breast cancer.
Potentially, MLPA offers some advantages over traditional
techniques. First, the high throughput of a PCR-based assay
has the appeal of scalability, which is important in terms of
cost/effectiveness (Farshid et al., 2011). Second, access to another
alternative testing assay for HER2 would be valuable for those
cases (2–3%) that remain equivocal after the completion of both
IHC and in situ hybridization testing and for discordant results
between IHC and in situ hybridization techniques (Farshid et al.,
2011), however specific studies focusing on this matter are yet to be
carried out and MLPA has yet to be clinically validated (Moelans
et al., 2011b). Moreover, some technical caveats should be men-
tioned, in particular: tissue morphology is lost and heterogeneity
can be missed, finally tissue contamination may occur. Altogether
these features should be carefully considered to avoid false-positive
and false-negative results and as a best practice advice microdissec-
tion or mesodissection are recommended (Moelans et al., 2011b),
best if performed based on IHC results.
In terms of biology of HER2+ tumors a “brand new” topic
is the recent demonstration of another biological mechanism
underpinning HER2 activation, i.e., activating mutations. Recent
next generation sequencing studies have brought to the front-line
the presence of HER2 mutations in breast cancer, a phenome-
non known since 2005 and that has been neglected due to the
most pervasive mechanism of HER2 gene amplification (Weigelt
and Reis-Filho, 2013). Data from eight breast cancer genome-
sequencing projects have identified 25 patients with HER2 somatic
mutations in cancers lacking HER2 gene amplification (Kan et al.,
2010; Banerji et al., 2012; Shah et al., 2012; Stephens et al., 2012;
Bose et al., 2013). Most of the mutations affect the tyrosine kinase
domain and some the ECD. Bose et al. (2013) have functionally
characterized 13 HER2 mutations using in vitro kinase assays, pro-
tein structure analysis, cell culture, and xenograft experiments.
Seven of these mutations were activating mutations and all of
these mutations were sensitive to the irreversible HER2/EGFR
tyrosine kinase inhibitor neratinib, thus validating HER2 somatic
mutations as drug targets for breast cancer treatment (Bose et al.,
2013).
In the meantime we wait for these critical preclinical data to
pave the way to HER2 sequencing-directed breast cancer clinical
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trials, the next challenge for pathologists will be to delineate
the identikit of HER2 mutation carriers. From data reported by
Bose et al. (2013) putative candidates seem to be identified with
ER positive breast carcinomas (both ductal and lobular carcino-
mas analyzed), either HER2 negative (score 0/1+) or showing
equivocal HER2 expression (score 2+).
We have therefore to come to terms that addiction to the con-
tinued activation of HER2 and its downstream signaling pathways
may be determined by more than one mechanism (Weigelt and
Reis-Filho, 2013) and pathologists may have soon to face the
challenge to add a further step of investigation in this context.
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